Latest Orphan drug Stories
EPI-743 phase 2b Friedreich's ataxia trial fully enrolled. Downingtown, PA (PRWEB) February 04, 2014 Edison Pharmaceuticals today announced that
EPI-743 in phase 2 development for Friedreich's ataxia MOUNTAIN VIEW, Calif., Feb.
Keller brings strong niche brand experience to high science agency. Chicago, IL (PRWEB) January 29, 2014 Discovery USA, a high-science marketing and
Annual Rare Disease Day event to benefit rare/orphan disease research CARLSBAD, Calif., Jan.
DURHAM, N.C., Jan.
CARLSBAD, Calif., Jan. 13, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
- A volcanic mudflow.